vs
雅培（ABT）与湘南美容医疗集团（SBC）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是湘南美容医疗集团的289.6倍（$11.5B vs $39.6M）。湘南美容医疗集团净利率更高（35.9% vs 15.5%，领先20.4%）。雅培同比增速更快（4.4% vs -10.9%）。雅培自由现金流更多（$2.6B vs $51.2M）。过去两年雅培的营收复合增速更高（7.2% vs -15.0%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
湘南美容医疗集团是总部位于日本的知名医疗服务提供商，核心业务覆盖美容整形、皮肤科诊疗、抗衰老健康护理等领域，在日本各地运营大量连锁诊所，同时服务本地居民及赴日就医的国际游客。
ABT vs SBC — 直观对比
营收规模更大
ABT
是对方的289.6倍
$39.6M
营收增速更快
ABT
高出15.3%
-10.9%
净利率更高
SBC
高出20.4%
15.5%
自由现金流更多
ABT
多$2.6B
$51.2M
两年增速更快
ABT
近两年复合增速
-15.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $39.6M |
| 净利润 | $1.8B | $14.2M |
| 毛利率 | 57.0% | 73.1% |
| 营业利润率 | 19.6% | 32.5% |
| 净利率 | 15.5% | 35.9% |
| 营收同比 | 4.4% | -10.9% |
| 净利润同比 | -80.8% | 117.2% |
| 每股收益（稀释后） | $1.01 | $0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTSBC
| Q4 25 | $11.5B | $39.6M | ||
| Q3 25 | $11.4B | $43.4M | ||
| Q2 25 | $11.1B | $43.4M | ||
| Q1 25 | $10.4B | $47.3M | ||
| Q4 24 | $11.0B | $44.4M | ||
| Q3 24 | $10.6B | $53.1M | ||
| Q2 24 | $10.4B | $53.1M | ||
| Q1 24 | $10.0B | $54.8M |
净利润ABTSBC
| Q4 25 | $1.8B | $14.2M | ||
| Q3 25 | $1.6B | $12.8M | ||
| Q2 25 | $1.8B | $2.5M | ||
| Q1 25 | $1.3B | $21.5M | ||
| Q4 24 | $9.2B | $6.5M | ||
| Q3 24 | $1.6B | $2.8M | ||
| Q2 24 | $1.3B | $18.5M | ||
| Q1 24 | $1.2B | $18.8M |
毛利率ABTSBC
| Q4 25 | 57.0% | 73.1% | ||
| Q3 25 | 55.4% | 70.6% | ||
| Q2 25 | 56.4% | 69.2% | ||
| Q1 25 | 56.9% | 79.7% | ||
| Q4 24 | 55.0% | 76.3% | ||
| Q3 24 | 55.8% | 81.5% | ||
| Q2 24 | 55.6% | 74.2% | ||
| Q1 24 | 55.2% | 72.1% |
营业利润率ABTSBC
| Q4 25 | 19.6% | 32.5% | ||
| Q3 25 | 18.1% | 36.6% | ||
| Q2 25 | 18.4% | 33.6% | ||
| Q1 25 | 16.3% | 51.1% | ||
| Q4 24 | 17.4% | 10.6% | ||
| Q3 24 | 17.5% | 26.1% | ||
| Q2 24 | 16.1% | 51.4% | ||
| Q1 24 | 13.9% | 44.6% |
净利率ABTSBC
| Q4 25 | 15.5% | 35.9% | ||
| Q3 25 | 14.5% | 29.6% | ||
| Q2 25 | 16.0% | 5.7% | ||
| Q1 25 | 12.8% | 45.4% | ||
| Q4 24 | 84.1% | 14.7% | ||
| Q3 24 | 15.5% | 5.3% | ||
| Q2 24 | 12.5% | 34.8% | ||
| Q1 24 | 12.3% | 34.2% |
每股收益（稀释后）ABTSBC
| Q4 25 | $1.01 | $0.15 | ||
| Q3 25 | $0.94 | $0.12 | ||
| Q2 25 | $1.01 | $0.02 | ||
| Q1 25 | $0.76 | $0.21 | ||
| Q4 24 | $5.26 | $0.05 | ||
| Q3 24 | $0.94 | $0.03 | ||
| Q2 24 | $0.74 | $0.20 | ||
| Q1 24 | $0.70 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $164.1M |
| 总债务越低越好 | $12.9B | $42.8M |
| 股东权益账面价值 | $52.1B | $248.3M |
| 总资产 | $86.7B | $380.4M |
| 负债/权益比越低杠杆越低 | 0.25× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资ABTSBC
| Q4 25 | $8.9B | $164.1M | ||
| Q3 25 | $7.7B | $127.4M | ||
| Q2 25 | $7.3B | $152.7M | ||
| Q1 25 | $6.8B | $132.1M | ||
| Q4 24 | $8.0B | $125.0M | ||
| Q3 24 | $7.8B | $137.4M | ||
| Q2 24 | $7.2B | — | ||
| Q1 24 | $6.7B | — |
总债务ABTSBC
| Q4 25 | $12.9B | $42.8M | ||
| Q3 25 | — | $21.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | — | $6.9M | ||
| Q4 24 | $14.1B | $6.6M | ||
| Q3 24 | — | $823.2K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABTSBC
| Q4 25 | $52.1B | $248.3M | ||
| Q3 25 | $51.0B | $248.0M | ||
| Q2 25 | $50.6B | $244.6M | ||
| Q1 25 | $48.8B | $226.4M | ||
| Q4 24 | $47.7B | $195.1M | ||
| Q3 24 | $39.8B | $205.0M | ||
| Q2 24 | $39.3B | $8.8M | ||
| Q1 24 | $38.8B | $9.0M |
总资产ABTSBC
| Q4 25 | $86.7B | $380.4M | ||
| Q3 25 | $84.2B | $321.4M | ||
| Q2 25 | $84.0B | $315.3M | ||
| Q1 25 | $81.4B | $284.6M | ||
| Q4 24 | $81.4B | $266.1M | ||
| Q3 24 | $74.4B | $296.5M | ||
| Q2 24 | $73.0B | $19.5M | ||
| Q1 24 | $72.5B | $19.8M |
负债/权益比ABTSBC
| Q4 25 | 0.25× | 0.17× | ||
| Q3 25 | — | 0.09× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | 0.30× | 0.03× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $52.0M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $51.2M |
| 自由现金流率自由现金流/营收 | 22.9% | 129.3% |
| 资本支出强度资本支出/营收 | 6.0% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.87× | 3.66× |
| 过去12个月自由现金流最近4个季度 | $7.4B | $23.3M |
8季度趋势，按日历期对齐
经营现金流ABTSBC
| Q4 25 | $3.3B | $52.0M | ||
| Q3 25 | $2.8B | $-20.9M | ||
| Q2 25 | $2.0B | $-8.3M | ||
| Q1 25 | $1.4B | $1.9M | ||
| Q4 24 | $2.9B | $-7.3M | ||
| Q3 24 | $2.7B | $5.0M | ||
| Q2 24 | $2.0B | $19.2M | ||
| Q1 24 | $1.0B | $3.7M |
自由现金流ABTSBC
| Q4 25 | $2.6B | $51.2M | ||
| Q3 25 | $2.3B | $-20.9M | ||
| Q2 25 | $1.5B | $-8.6M | ||
| Q1 25 | $933.0M | $1.7M | ||
| Q4 24 | $2.1B | $-7.9M | ||
| Q3 24 | $2.1B | $4.6M | ||
| Q2 24 | $1.4B | $18.3M | ||
| Q1 24 | $627.0M | $3.0M |
自由现金流率ABTSBC
| Q4 25 | 22.9% | 129.3% | ||
| Q3 25 | 20.2% | -48.3% | ||
| Q2 25 | 13.9% | -19.9% | ||
| Q1 25 | 9.0% | 3.5% | ||
| Q4 24 | 19.6% | -17.8% | ||
| Q3 24 | 20.2% | 8.7% | ||
| Q2 24 | 13.8% | 34.5% | ||
| Q1 24 | 6.3% | 5.4% |
资本支出强度ABTSBC
| Q4 25 | 6.0% | 2.0% | ||
| Q3 25 | 4.4% | 0.1% | ||
| Q2 25 | 4.5% | 0.7% | ||
| Q1 25 | 4.7% | 0.5% | ||
| Q4 24 | 6.6% | 1.3% | ||
| Q3 24 | 5.2% | 0.8% | ||
| Q2 24 | 5.1% | 1.6% | ||
| Q1 24 | 4.0% | 1.3% |
现金转化率ABTSBC
| Q4 25 | 1.87× | 3.66× | ||
| Q3 25 | 1.70× | -1.63× | ||
| Q2 25 | 1.15× | -3.39× | ||
| Q1 25 | 1.07× | 0.09× | ||
| Q4 24 | 0.31× | -1.12× | ||
| Q3 24 | 1.64× | 1.77× | ||
| Q2 24 | 1.51× | 1.04× | ||
| Q1 24 | 0.84× | 0.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
SBC
| Franchising | $10.3M | 26% |
| Medical Corporation Shobikai | $8.1M | 21% |
| Medical Corporation Nasukai | $7.2M | 18% |
| Management Services | $6.3M | 16% |
| Rental Services | $4.3M | 11% |
| Medical Corporation Association Furinkai | $3.0M | 8% |
| Japan Medical And Beauty Inc | $656.5K | 2% |
